Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 27; 77(13):1253-62.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.